Abstract
Water soluble aclalubicin hydrochloride(ACR, Aclacinone®, Yamanouchi Pharmaceutical Comp. Japan) was dissolued into Lipiodol Ultra-Fluid®(Kodama Co. Ltd. Japan) with an addition of an equivalent amount of 7% sodium bicarbonate (Meylon®, Otuska Pharm. Co. Ltd. Japan). A maximum concentration of ACR in LPD reached to approximately 20 mg/ml. Release of ACR from ACR/LPD solution was documented for more than 6 weeks period. Intraarterial infusion of ACR/LPD (1.5 mg/0.1 ml/kg) reduced tumor growth significantly(P<0.01-0.05)in rabbit VX-2 hepatoma model comparing to groups they received ACR/H2 O solution (ACR 1 mg/kg, 1.5 mg/kg), LPD alone(0.1 ml/kg), and ACR/LPD (1.0 mg/0.1 mg/kg). These results suggest that the ACR/LPD solution with 7% sodium bicarbonate may be an active agent for intraarterial targeting chemotherapy which has delayed releasing of ACR.
